This review concluded that rifaximin was similar to other oral therapies in its clinical efficacy for hepatic encephalopathy and it had fewer side-effects. This was a well-conducted review, but the reliability of the conclusions may be affected by the observed statistical variation and the lack of participant information.
Study selection
Randomised controlled trials were eligible for inclusion if they reported on the effectiveness of rifaximin, compared with non-absorbable oral disaccharides or other antibiotics, in patients with hepatic encephalopathy. Patients had to be older than 18 years, with a diagnosis of reversible neurological decline secondary to end-stage liver disease. The primary outcomes were the improvement in neurological function; the grade of hepatic encephalopathy, according to Conn's modification of the Parsons Smith classification; and safety. Secondary outcomes were the reduction in serum ammonia levels and changes in psychometric measures (mental status, asterixis [hand tremor], electroencephalograph characteristics and portosystemic encephalopathy sum) at the end of the treatment.
Most studies evaluated rifaximin 1,200mg per day in three doses; some evaluated 1,100mg in two doses. Control arms received non-absorbable oral disaccharides (lactulose 45 to 120mL per day or lactitol 60g per day) or antibiotic therapy (neomycin 3,000 or 4,500mg per day or paromomycin 1,500mg per day, in three doses). Most trials that used nonabsorbable oral disaccharides aimed to induce several soft bowel movements per day, but none of them reported how they monitored their participants. Treatment duration ranged from seven days to six months.
Two reviewers independently assessed trials for inclusion.
Assessment of study quality
The quality of included trials was assessed using the Cochrane Collaboration's risk of bias tool, which covers the method of randomisation; allocation concealment; blinding of patients, caregivers and outcome assessors; and reporting of loss to follow-up and whether all patients were accounted for in the analysis and reporting. The assessment also covered the reporting of a sample size calculation and if this size was achieved; a clear definition of the primary outcomes; and if a crossover design was used.
The assessment was performed by two independent reviewers.
Data extraction
The proportions of patients with improvement in neurological function and common side-effects were extracted and used to calculate odds ratios with 95% confidence intervals. Mean differences were calculated for serum ammonia levels and psychometric measures along with 95% confidence intervals. Two independent reviewers extracted the data.
Methods of synthesis
Pooled odds ratios and weighted mean differences were obtained using random-effects meta-analysis with inversevariance weighting. Statistical heterogeneity was assessed using Ι² and Χ² (p<0.1 indicated significant heterogeneity). The potential reasons for heterogeneity were explored. The data were analysed on an intention-to-treat basis and the last observation carried forward was used for patients with missing data. Only data from the first period of crossover trials were included. For the primary outcome, subgroup analyses were performed by control treatment regimen (oral 
Results of the review
Twelve trials were included in the review, with 565 patients (range 14 to 136). Five described the randomisation methods; eight had clearly reported allocation concealment; most had patient blinding to treatment; and six reported observer blinding to treatment. The methods for handling missing data, the descriptions of drop-outs, and power calculations were not adequately reported in any of the included trials.
Neurological function: Seven trials compared rifaximin with disaccharides and reported that both groups experienced either full resolution of hepatic encephalopathy or a clinically significant improvement, but there was no statistically significant difference between the groups. A similar result was seen in the five trials comparing rifaximin with antibiotics. In the combined analysis of all 12 trials, the results favoured rifaximin, but were not statistically significant (OR 1.96, 95% CI 0.94 to 4.08; Ι²=27%).
Adverse events: Patients receiving rifaximin had lower rates of diarrhoea (OR 0.20, 95% CI 0.04 to 0.92; eight trials; Ι²=66%), but the rates of abdominal pain, nausea, anorexia and weight loss were similar between the two groups. The combined analysis of all adverse events showed fewer events with rifaximin than with control (OR 0.27, 95% CI 0.12 to 0.59; nine trials; Ι²=69%).
Serum ammonia: Seven trials reported a statistically significant reduction in serum ammonia at the end of treatment in both groups. There was no statistically significant difference between the groups in the meta-analysis of all trials or of subgroups with disaccharides or antibiotics as the control. Statistical heterogeneity was very high for all serum ammonia analyses (Ι²=83% or more).
Psychometric parameters: Rifaximin improved electroencephalographic characteristics (WMD -0.21, 95% CI -0.33 to -0.09; four trials; Ι²=0) and portosystemic encephalopathy (WMD -2.33, 95% CI -2.68 to -1.98; three trials; Ι²=21%). There was no statistically significant difference between rifaximin and control for improvement in mental status and asterixis.
Trials with a high risk of bias were excluded from all analyses and the results remained consistent.
